<DOC>
	<DOCNO>NCT00771043</DOCNO>
	<brief_summary>Phase IV , proof-of-concept , randomize , open-label , multi-center , two-arm , 9-month study evaluate neuroprotective effect Natalizumab ( TYSABRIÂ® ) Interferon beta-1a ( AVONEXÂ® ) treatment initiated time acute optic neuritis ( AON ) measure RNFL thickness Optical Coherence Tomography patient Relapsing Remitting Multiple Sclerosis ( RRMS ) .</brief_summary>
	<brief_title>A Proof-of-Concept Study Correlate Retinal Nerve Fiber Layer Changes Patients With Multiple Sclerosis Treated With Natalizumab Interferon Beta 1-a</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Diagnosis RRMS . Patients unilateral AON consistent Multiple Sclerosis ( MS ) . Treatment intravenous methylprednisolone ( IVMP ) 1gm daily three day onset AON , without taper , complete within 14 day AON symptom onset . Age 1855 year . Expanded Disability Status Scale ( EDSS ) 0 5.0 . Understand sign inform consent . History presence progressive multifocal leukoencephalopathy ( PML ) . Diagnosis Primary Progressive Multiple Sclerosis ( PPMS ) Secondary Progressive Multiple Sclerosis ( SPMS ) . Immunecompromised judgment Investigator . History presence clinically significant medical illness laboratory abnormality , opinion investigator Sponsor , would preclude participation study . Concomitant ophthalmologic disorder ( e.g . diabetes , macular degeneration , etc ) . Previous history severe disc edema , hemorrhage , &gt; 1 confirm optic neuritis ( ON ) recent ON symptom onset le 12 month ago . Previous treatment &gt; 1 Disease Modifying Therapy ( DMT ) . Previous treatment investigational product MS , immunosuppressant cytotoxic therapy . Previous treatment TYSABRI® Women postmenopausal , surgically sterile , willing practice contraception . Women pregnant , breast feeding , plan become pregnant . Involved study protocol simultaneously without prior approval . Determined suitable study participation Investigator and/or Sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>